Teva touts safety profile of once-monthly schizophrenia therapy

Teva Pharmaceuticals has shared new safety data from the Phase III SOLARIS trial and a Phase I study of extended-release subcutaneous olanzapine, TEV-‘749, showing that none of the patients in the two studies experienced post-injection delirium/sedation syndrome (PDSS).